ANI Pharmaceuticals Inc (OQ:ANIP)
Business Focus: Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 210 Main Street West BAUDETTE MN 56623 |
| Tel: | 1-212-4522793 |
| Website: | https://www.anipharmaceuticals.com |
| IR: | See website |
| Key People | ||
| Nikhil Suresh Lalwani President, Chief Executive Officer, Director | Stephen P. Carey Chief Financial Officer, Senior Vice President | Krista Davis Chief Human Resource Officer |
| Meredith Cook Senior Vice President, General Counsel, Company Secretary | Chad Gassert Senior Vice President - Corporate Development and Strategy | Ori Gutwerg Senior Vice President - Generics |
| James G. Marken Senior Vice President - Operations | Christopher K. Mutz Senior Vice President, Head of Rare Diseases | Muthusamy Shanmugam Director, Head of Research and Development, Chief Operating Officer - Novitium Operations |
| Business Overview |
| ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, ANI Pharmaceuticals Inc revenues increased 54% to $486.8M. Net income applicable to common stockholders totaled $15.5M vs. loss of $49.5M. Revenues reflect Generics Established Brands and Other segment increase of 36% to $374.7M, Rare Disease segment increase from $41.7M to $112.1M. Net Income reflects Restructuring activities decrease of 80% to $1.1M (expense). |
| Employees: | 642 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $1,465M as of Dec 31, 2023 |
| Annual revenue (TTM): | $486.82M as of Dec 31, 2023 |
| EBITDA (TTM): | $107.89M as of Dec 31, 2023 |
| Net annual income (TTM): | $15.48M as of Dec 31, 2023 |
| Free cash flow (TTM): | $108.47M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $64.55M as of Dec 31, 2023 |
| Shares outstanding: | 20,991,171 as of Mar 27, 2024 |
| Index Membership: | S&P 600 Small Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.